How to Prepare Registration Dossiers for Overseas Market Authorization of Sterilization and Disinfection Equipment

Key Takeaways

Preparing registration dossiers for sterilization and disinfection equipment for overseas markets is not simply a matter of translating existing documents. The first step is to determine the product's regulatory classification and registration pathway in the target country. Manufacturers should confirm whether the device is regulated as a medical device, then identify the appropriate route—such as premarket notification, registration, or marketing authorization—based on risk class, and clarify the applicant entity.

During dossier preparation, systematically review existing technical documentation under NMPA, CE, FDA, or ISO 13485 systems, including performance validation, risk management, clinical evaluation, and labeling. Assess which documents can be directly reused and which must be localized to meet local regulatory requirements.

Common risks include overlooking local technical document format differences, lacking a local authorized representative, unclear certificate control rights, and undefined post-market maintenance obligations. It is recommended that manufacturers confirm the target country's registration classification, agent responsibilities, language requirements, and renewal cycle before project initiation. Establishing a reusable core technical document master file, supplemented by country-specific differences, can reduce redundant work and the risk of deficiency letters in multi-country registrations.

Applicable Scenarios and Core Questions

Sterilization and disinfection equipment are essential infection control devices used in hospitals, clinics, and laboratories. They include autoclaves, ethylene oxide sterilizers, low-temperature plasma sterilizers, ultraviolet disinfection devices, and washer-disinfectors. When planning to export such equipment, the first question to answer is whether the product is regulated as a medical device in the target country. Definitions and classifications vary by country. For example, in the United States, such products may fall under FDA regulation as medical devices; in the European Union, they may be Class I or Class IIa; and in some Southeast Asian countries, they may be classified as medical devices or health products. A misclassification can lead the entire registration pathway astray, wasting time and resources.

The second core question is to define the registration objective. Is the company planning to enter a single country or multiple GHWP member countries? Is it a first-time registration, or does the company already hold an NMPA registration certificate, CE certificate, or FDA 510(k)? These circumstances directly influence dossier preparation strategy. If mature technical documentation already exists, the focus should be on localization and gap analysis. If starting from scratch, a full technical file must be built according to the target country's regulatory requirements.

The third question is to identify stakeholders. Besides the manufacturer, it is necessary to confirm whether a local agent, authorized representative, or license holder is required. Many countries require foreign manufacturers to designate a local agent responsible for communication with regulatory authorities, receiving adverse event reports, handling recalls, and coordinating inspections. Overlooking this requirement can result in rejection during the formal review stage.

Therefore, the first action in preparing registration dossiers is not writing documents, but conducting a regulatory assessment. Manufacturers must clarify product classification, registration pathway, applicant entity, and local agent requirements before determining which documents are needed and at what depth.

Registration Determination Logic

Before finalizing the document checklist, the registration pathway should be mapped out using the following logic:

• Step 1: Confirm whether the product falls within the target country's medical device regulatory scope. For example, in some Southeast Asian countries, a simple ultraviolet disinfection lamp may be classified as a household appliance, but if it claims a germicidal medical use, it would be considered a medical device. Large steam sterilizers, on the other hand, are typically classified as medical devices. This step can be accomplished through the target country's regulatory authority website, local agents, or regulatory databases.
• Step 2: Determine the risk class and registration category. Sterilization and disinfection equipment are generally classified according to intended use, contact site, and risk level. In the EU, sterilizers are mostly Class IIa, but those with measuring functions may be Class IIb. The FDA classifies most sterilization equipment as Class II, requiring 510(k) submission. NMPA classifies sterilization equipment as Class II or Class III. Other countries may follow international classification with minor variations. The risk class directly determines the depth of technical documentation and whether clinical evidence is required.
• Step 3: Identify the registration pathway. Pathways generally fall into “standard registration” and “simplified registration.” Some countries accept CE or FDA certificates as a basis for accelerated approval; for example, certain Middle Eastern and Latin American countries allow a “recognized certificate” pathway. GHWP member countries, however, generally require local registration, though approvals from other markets can serve as supporting evidence. Companies should prioritize markets with mature regulatory requirements and predictable review timelines as initial overseas registration targets, gaining experience before expanding.
• Step 4: Assess the reusability of existing documentation. If a company already holds an NMPA registration certificate, technical documents, test reports, risk management files, and clinical evaluation data are typically available but may need format and language conversion. If CE technical files exist, these can generally serve as the master template, supplemented by country-specific differences. If only ISO 13485 system documents are available, additional product standards and performance verification data will be needed. A gap analysis can clarify what new tests and documents are required.
• Step 5: Confirm post-market obligations. After registration, manufacturers typically must fulfill obligations such as annual reporting, change notifications, adverse event reporting, and label updates. It must be clear whether the local agent or the manufacturer is responsible for these obligations, and this should be documented in an agreement before registration. Neglecting post-market maintenance can lead to certificate suspension or revocation, affecting continued sales in that country.

Documentation and Evidence

A typical dossier for overseas registration of sterilization and disinfection equipment can be organized into eight modules: administrative documents, product technical documentation, quality system documentation, performance verification documentation, risk management documentation, clinical evaluation documentation, labeling and instructions for use, and post-market surveillance documentation.

Administrative documents include the application form, manufacturer business license, ISO 13485 certificate, free sale certificate, letter of authorization, and local agent appointment. These documents often require notarization, translation, and consular legalization, depending on the target country. Companies should prepare multiple originals in advance to avoid delays caused by long authentication processes.

Product technical documentation is the core of the registration dossier. It typically includes product description, model specifications, working principle, raw materials, manufacturing process, intended use, environmental conditions, technical parameters, and packaging information. For sterilization and disinfection equipment, additional details are required, such as the sterilization mechanism, key components (e.g., chamber, heating system, sensors), control system, software version, and methods for monitoring sterilization efficacy.

Performance verification documentation provides evidence of safety and effectiveness. For sterilizers, this includes sterilization performance validation data such as temperature range, time, biological indicator challenge tests, chemical indicator verification, leak rate testing, and temperature uniformity testing. For disinfection equipment, microbial kill rate tests, ultraviolet intensity tests, and effective cleaning cycle validation are required. These tests should be conducted by qualified laboratories and reports issued in accordance with local requirements.

Risk management documentation typically includes an ISO 14971 risk management report, FMEA analysis, and risk assessment with control measures. Sterilization and disinfection equipment involve hazards such as high temperature, high pressure, chemicals (e.g., ethylene oxide), and ultraviolet radiation. The risk analysis must cover all intended and reasonably foreseeable misuse scenarios. If the target country accepts ISO standards, ISO 14971-based risk management files can generally be reused, but some countries may require additional verification of specific risk control measures.

Clinical evaluation documentation depends on the risk class and whether the product is exempt from clinical evidence requirements. Most sterilization and disinfection equipment can fulfill clinical evaluation through performance testing and comparison with existing products. However, if the product uses novel technology or a different intended purpose, clinical trial data may be required. Companies should check the target country's exemption list early to avoid unnecessary clinical studies.

Labeling and instructions for use must comply with local language, format, and content requirements. In addition to basic product information, labels must include instructions for use, warnings, contraindications, sterilization cycle parameters, fault information, maintenance methods, and Unique Device Identification (UDI) where applicable. In some Middle Eastern countries, labels must also include the local registration number and agent information. Translation is not word-for-word; it must conform to local medical and regulatory terminology.

Post-market surveillance documentation is required for long-term maintenance. This includes vigilance system procedures, adverse event report templates, annual update report templates, and change notification procedures. Even if these documents are not required at the initial registration, regulatory authorities expect companies to have such procedures and records as part of their quality system.

Common Mistakes

• Ignoring the target country's regulatory classification and directly applying NMPA or CE classification, leading to incorrect submission category.
• Relying on a translation agency to directly translate existing files without restructuring them according to the target country's technical format, resulting in significant deficiencies.
• Omitting the requirement for a local authorized representative and only starting to search for an agent upon receiving a deficiency notice, delaying the registration timeline.
• Assuming that a CE certificate allows direct market access in GHWP member countries, without understanding that local registration and supplementary documents are still required.
• Submitting performance verification reports that are not accepted by the target country because the test standards, laboratory qualifications, or sample sizes do not meet local requirements.
• Submitting incomplete risk management documentation—for example, only an FMEA without a risk management plan or verification records for risk control measures.
• Failing to localize labels and instructions for use according to local language and measurement unit requirements, sometimes even mixing traditional and simplified Chinese or using incorrect units.
• Neglecting post-market maintenance obligations, failing to assign a responsible person for adverse event and change management after obtaining the registration certificate, leading to certificate suspension.

Manufacturer Preparation Checklist

• 30 days before project kickoff, complete an investigation of the target country's regulatory classification and registration pathway, and produce a written report.
• Assign a project leader and coordination team, clearly defining the roles of the manufacturer, agent, testing laboratory, and translation agency.
• Create an inventory of existing documents, listing all available NMPA, CE, FDA, and ISO 13485 certificates and documents, and noting their validity dates.
• Conduct a gap analysis to determine which new tests, documents, and translations are needed.
• Determine whether a local authorized representative is required and how to select one, signing an agreement that includes responsibility clauses.
• Organize product technical documentation and design drawings, ensure version control, and translate them into the target country's required language.
• Collect performance verification reports, biocompatibility data, sterilization validation, safety testing, and other data, confirming they meet local standards.
• Prepare risk management documentation, clinical evaluation reports, or exemption declarations, and adjust them according to local regulatory formats.
• Create product labels and instructions for use that meet local requirements, and have them reviewed by regulatory personnel.
• Establish a post-market surveillance system and document templates, including complaint, adverse event, recall, and annual update procedures.
• Plan the registration fee budget and timeline, allowing for deficiencies and review wait times.

AIMEILI Perspective

Manufacturers often mistakenly believe that overseas registration is simply “translating CE documents,” but each country has its own technical document format, language requirements, and review focus. For example, some countries require the original authorization letter from the local agent; others require performance test reports from a laboratory accredited in that country; and still others require specific warning statements in the instructions for use. Without a preliminary gap analysis, companies may only discover missing core evidence upon receiving a deficiency letter, stalling the entire project.

The first step in a project should not be writing documents but defining the regulatory framework. We recommend completing a target-country classification research first, then consulting an experienced local agent or consultancy to confirm specific document requirements. This avoids rework caused by classification errors. Companies should also establish a core technical document master file early on, organizing all basic product descriptions, performance data, risk analyses, and clinical evaluations under a unified standard. This master file can support multi-country registrations.

Which documents can be reused? Documents based on international standards—such as ISO 13485 certificates, ISO 14971 risk management files, IEC 61010 safety test reports, and sterilization validation data—are generally reusable. Which documents must be localized? Product instructions for use, labels, clinical evaluation reports, electrical safety test reports (some countries require local testing), and administrative documents such as free sale certificates all require localization. Be aware that some countries do not directly recognize other countries' registration certificates but may reference CE or FDA review opinions; therefore, retaining original review documentation can significantly help accelerate registration.

Local agent and certificate control rights are critical. The registration certificate is usually held by the manufacturer, but the local agent handles communication with the regulatory authority. If the agent changes or the agreement is terminated, the change must be processed promptly, or the certificate may become invalid. Additionally, companies should design a certificate holding strategy to avoid losing an entire market due to suspension of a single certificate. Post-market maintenance is not optional; it is a continuous obligation. Companies need to establish adverse event reporting processes in the target country and assign a dedicated person to track regulatory changes to ensure timely certificate renewal, change notification, and annual reporting.

To reduce the cost of multi-country registration, the key is to build a “core technical file +” architecture. The core technical file contains product-general data and test reports under international standards. For registration in different countries, only the country-specific administrative documents, language versions, and supplemental differences need to be prepared. This avoids repeating full testing and documentation for every country. We recommend selecting two or three representative markets as pilot countries when starting multi-country registration. Refine the process and templates through these pilots, then replicate to other markets. This approach significantly reduces redundant work and the risk of deficiencies.

Frequently Asked Questions

Can we apply for registration in Southeast Asian countries without a CE certificate?

Yes. Many Southeast Asian countries allow registration using an ISO 13485 certificate and test reports that comply with local standards; a CE certificate is not mandatory. However, without a recognized registration record such as CE or FDA, the registration timeline may be longer, and technical document review will be more thorough. It is advisable to confirm whether the target country offers a registration exemption or simplified pathway, and to prepare comprehensive performance validation and risk management documentation.

How is clinical evaluation performed for sterilization and disinfection equipment? Is a clinical trial required?

Most sterilization and disinfection equipment are Class II devices. Clinical evaluation can typically be completed through substantial equivalence comparison with similar marketed products, combined with performance testing and literature data; a clinical trial is not required. However, if the product employs a new sterilization technology or is intended for a new risk population, the regulatory authority may require clinical data. It is recommended to search the target country for classification and marketing history of such products, and to consult a professional agency if necessary.

Must all registration documents be translated into the target country's language? How are translation and notarization handled?

Yes, almost all non-English-speaking countries require registration documents in the local language, especially instructions for use and labels. Many countries require that translations be notarized or issued by a translation agency recognized by the target country. Some may even require an original translation with a translator's declaration. Before submission, confirm the translation requirements with the target country agent, including format, stamping, and notarization, to avoid rejection due to translation issues.

What documents must be submitted annually after registration is completed?

Most countries require an annual update after market entry. This typically includes product change information, quality system status, adverse event reports, sales data, and certificate validity confirmation. Some countries require proof of the local agent's continuing authorization, and some require payment of annual fees. If a major design change or intended use change occurs, a new registration or change application may be required. Companies should establish an annual calendar to ensure timely submission.